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Rhoptry-associated protein 2 (RAP2) is known to be discharged from rhoptry onto the membrane surface of 
infected and uninfected erythrocytes (UEs) ex vivo and in vitro and this information provides new insights into the 
understanding of the pathology of severe anemia in falciparum malaria. In this study, a hexahistidine-tagged re-
combinant protein corresponding to residues 5-190 of the N-terminal of Plasmodium falciparum RAP2 (rN-RAP2) 
was produced using a new method of solubilization and purification. Expression was induced with D-lactose, a 
less expensive alternative inducer to the more common isopropyl-β-d-thio-galactopyranosidase. The recombinant 
protein was purified using two types of commercially-available affinity columns, iminodiacetic and nitrilotriacetic. 
rN-RAP2 had immunogenic potential, since it induced high titers of anti-RAP2 antibodies in mice. These antibodies 
recognized full-length RAP2 prepared from Triton X-100 extracts from two strains of P. falciparum. In fact, the an-
tibody recognized a 29-kDa product of RAP2 cleavage as well as 82 and 70-kDa products of RAP1 cleavage.  These 
results indicate that the two antigens share sequence epitopes. Our expressed protein fragment was shown to contain 
a functional epitope that is also present in rhoptry-derived ring surface protein 2 which attaches to the surface of 
both infected and UEs and erythroid precursor cells in the bone marrow of malaria patients. Serum from malaria 
patients who developed anemia during infection recognized rN-RAP2, suggesting that this protein fragment may be 
important for epidemiological studies investigating whether immune responses to RAP2 exacerbate hemolysis in 
falciparum malaria patients. 
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Rhoptry-associated protein 2 (RAP2) is a 398-amino 
acid protein encoded by a single exon located on chro-
mosome 5 of Plasmodium falciparum (Perez-Leal et al. 
2005). It is discharged from rhoptry, an apical organelle 
of the merozoite, onto the surface of the erythrocyte 
membrane during the blood stage of malaria infections. 
This discharge leads to the formation of a parasito-
phorous vacuole (PV) membrane. RAP2 is considered 
to be an important candidate for vaccine development, 
since monkeys immunized with RAP2 were partially 
protected against parasite challenge (Perrin et al. 1985, 
Ridley et al. 1990).
Douki et al. (2003) and Layez et al. (2005) provided 
new insights into the rhoptry antigen, especially RAP2, 
by discharging this antigen onto the surface of unin-
fected erythrocytes (UEs) ex vivo and in vitro. These 
authors suggested that the anti-RAP2 specific immune 
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response plays a role in the pathology of severe anemia 
by inducing lysis of UEs immediately after discharge of 
this antigen onto the surface membrane.
Saul et al. (1992) cloned the entire RAP2 gene and 
described its expression and purification using a hexa-
histidine system. Their methods yielded a low level of 
expression; further, the purification of RAP2 presented 
a range of difficulties due to the protein’s lipophilicity. 
Expression in their study was induced using isopropyl-β-
d-thio-galactopyranosidase (IPTG), which substantially 
raised the cost of protein production due to the many li-
ters of culture necessary to obtain a reasonable amount 
of protein. The authors described that RAP2 precipitates 
even at very low concentrations in the absence of a strong 
detergent; 6 M guanidine was needed to solubilize inclu-
sion bodies. Furthermore, Saul et al. (1992) reported that 
recombinant RAP2 could be eluted effectively only with 
a denaturation buffer containing 0.5 M imidazole (iDB) 
and not with a pH gradient.
In the present study, a hexahistidine-tagged RAP2 
fragment containing the N-terminal (N-RAP2) resi-
dues 5-190 of P. falciparum RAP2 was produced. We 
achieved efficient induction of expression in Escheria 
coli using d-lactose as a less expensive alternative to 
IPTG. Furthermore, we compared the purifying power 
of two types of commercially-available affinity col-
umns, iminodiacetic (Ni-IDA) and nitrilotriacetic (Ni-
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NTA). Our expression system is relevant for future stud-
ies aiming to understand the molecular mechanisms of 
host-parasite interactions in falciparum malaria. 
MATERIALS AND METHODS
Cloning of N-RAP2 - Bioinformatic analyses were 
performed using DNASTAR software (DNASTAR 
Inc). The following primers were used in this study: 
5’ - ggatccTTTTATGTATTAGTTTT-3’ (sense) and 5’ - 
gaattcGGTGGTGGTGGTGGATCCTACTATAAAG-3’ 
(an-tisense).  These primers were designed based on the 
GenBank sequence XM-001351539. P. falciparum 3D7 
parasites were cultured in vitro using routine methods and 
parasite extracts were prepared as previously described 
(Ljungström et al. 2004a, b). For amplification of a  585 
bp fragment containing the N-terminal residues 5-190 of 
P. falciparum RAP2 (N-RAP2), PCR was performed 
with the following parameters: 94ºC for 5 min, 35 cycles 
of 94ºC for 1.5 min, 60ºC for 1 min, 72ºC for 1.5 min 
and a final 10 min incubation at 72ºC . After agarose gel 
purification, the fragment was cloned into the pGEM T 
easy vector (Promega) and transformed into E. coli DH5α. 
White transformant colonies were screened using PCR. 
The sequence of the cloned N-RAP2 DNA was con-
firmed using the Thermo sequence primer cycle se-
quencing kit. After digestion with Bam H1 and Eco R1, 
the N-RAP2 fragment was sub-cloned into the pRSET 
vector (Invitrogen) and transformed into E. coli TG1. 
Colonies were screened by PCR using a primer for the 
T7 promoter (sense) and a RAP2 primer (anti-sense). 
Expression and purification of recombinant N-RAP2 
- Bacterial extract was prepared based on the methods of 
Petty (1996) with some modifications developed by our 
group. After transforming E. coli BL21 cells with the 
RAP2-pRSET construct, a single transformant colony was 
used to grow a 1 L culture in M9 synthetic medium sup-
plemented with 100 µg/mL ampicillin at 30°C. When an 
optical density of 0.8 was reached, 10 g/L of d-lactose was 
added and the culture was incubated for another 16 h. 
The culture was harvested by centrifugation (4000 rpm 
/15 min/4°C) and resuspended in MCAC buffer (20 mM 
Tris-HCl, pH 7.9; 0.5 M NaCl; 10% glycerol; 0.15 mM 
PMSF) containing 33 µL of a protease inhibitory cocktail 
(0.1 ug/mL leupeptin and 0.1 ug/mL pepstatin).  The cells 
were resuspended in the ratio of 2.5-5.0 mL of buffer per 
50 mL of culture. Triton X-100 was added and three cy-
cles of freezing in liquid nitrogen and thawing at RT were 
performed. Deoxyribonuclease I was added at the con-
centration recommended by the supplier and the induced 
extract was harvested by centrifugation (15.000 rpm/ 
15 min/4°C). Pellets were resuspended in denaturation 
buffer (DB) (8 M urea; 10 mM 2-mercaptoethanol; 
20 mM Tris-HCl, pH 7.9; 0.5 M NaCl; 10% glycerol; 
0.15 mM PMSF) and incubated at RT for 1-2 h on a hori-
zontal shaker. The extract was then harvested by cen-
trifugation (15.000 rpm/15 min/rt) and the denatured 
supernatant was stored at -80°C. A 5-L culture was also 
induced using 10 g/L of d-lactate and the denatured su-
pernatant was prepared as described above.  
Prior to purification, Ni-IDA and Ni-NTA affin-
ity columns were equilibrated with MCAC buffer. The 
pH of the denatured supernatant was readjusted with 
5N NaOH to 9.0 and the supernatant was incubated in 
batch with the affinity resin for 1 h at RT with rota-
tion. In the Ni-NTA column, the resin was washed with 
30 mL of DB at pH 6.3 adjusted with HCl 1M.  It was 
gradually washed as follows with denaturation buffer 
(DB) containing increasing concentrations of imidazole 
(iDB): 1st, 10 mL of DB supplemented with 5 mM iDB; 
2nd, 10 mL of 10 mM iDB; 3rd, 10 mL each of 15 mM 
iDB and 20 mM of iDB; finally, 10 mL of DB pH 5.9. 
The bound protein was eluted with DB at pH 4.5. Ni-
IDA resin was similarly washed with 120 mL of DB in 
a 0-100 mM iDB gradient, and all elutions were per-
formed with 1M iDB. For each resin, the purity of the 
final eluate was analyzed by SDS-PAGE and Coomass-
ie blue staining. 
Preparation of anti-rN-RAP2 serum from mice - rN-
RAP2 purified from the Ni-NTA column was quanti-
fied and 4 µg of protein was homogenized in complete 
Alum adjuvant. Three female BALB/c mice (6-8 weeks 
old) were immunized by intraperitoneal injection. After 
15 days, a booster was performed under the same con-
ditions. Sera were collected from the tail vein 15 days 
after the booster.
Preparation of total extract from Plasmodium 3D7 
for Western blotting - A culture of P. falciparum, clone 
FCR3, was provided as a gift by Fabio Costa (Instituto de 
Biologia – Universidade de Campinas). Ring stage-rich 
parasites were subjected to osmotic lysis by diluting them 
150 fold with ultrapure water containing protease inhibi-
tors (0.1 µg/mL leupeptin, 0.1 µg/mL pepstatin, 0.15 mM 
PMSF and 5 mM EDTA). After 16 h of incubation at 
4ºC, the cellular lysate was harvested by centrifugation 
(15.000 rpm/4ºC/2 h) and washed twice with ultrapure 
water containing protease inhibitors in order to eliminate 
any trace of hemoglobin. The pellet was resuspended in 
100 µL of 1% Triton X-100 and incubated for 30 min on 
ice. Subsequently, the protein was harvested by centrifu-
gation and the supernatant subjected to immunoblotting. 
Immunoblotting to detect reactivity against rN-RAP2 
- SDS-PAGE and Western blots were performed follow-
ing routine methods. First, to confirm the expression 
of rN-RAP2, a lysate from E. coli BL21 pLysS trans-
formed with the RAP2-pRSET plasmid was blotted onto 
a nitrocellulose membrane and probed with a commer-
cially-available monoclonal antibody (mAb) (46-1008, 
Invitrogen, Carlsbad, CA, USA) against the histidine 
tag. Second, conformational and linear epitopes of rN-
RAP2 were compared with those of native RAP2 ob-
tained from extracts of P. falciparum 3D7 and FCR3 
parasites.  E. coli lysates and falciparum extracts were 
blotted onto nitrocellulose membranes and probed us-
ing murine anti-rN-RAP2 IgG antibodies raised as 
described above. Third, we determined whether rN-
RAP2 contains a functional RSP2 epitope using an 
RSP2 mAb generously provided by Dr. Jurg Gysin from 
the Mediterranean University (Marseille, France). In all 
three blots, goat anti-mouse peroxidase was used as the 
secondary antibody. 
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In order to determine whether natural antibodies 
recognize the recombinant protein, purified rN-RAP2 
was blotted onto a nitrocellulose membrane and incu-
bated with human sera from malaria-infected individu-
als (a kind gift from Dr. Marcus Lacerda of Fundação 
de Medicina Tropical, state of Amazonas, Manaus, Bra-
zil). Two black spots were drawn with a pencil to allow 
precise placement of the protein onto the nitrocellulose 
membrane. Goat anti-human peroxidase was used as 
the secondary antibody. Tetramethylbenzidine was used 
as the substrate in all reactions and the reactions were 
stopped after 30 min by washing with distilled water. 
RESULTS
Sequencing and expression of recombinant N-termi-
nal RAP2 - The 585 bp fragment containing the N-termi-
nal residues 5-190 of P. falciparum RAP2 was sequenced 
and confirmed with 97 score the identity of the RAP2 
fragment with RAP2 sequence XM_001351539 (Fig. 1). 
The rN-RAP2 was expressed in E. coli BL21 pLysS us-
ing d-lactose as an inducer. An antibody against the His 
tag was used to confirm the presence of hexahistidine in 
the ~27-29 kDa protein (Fig. 2). 
Purification of rN-RAP2 - The rN-RAP2 was puri-
fied using two commercially-available affinity resins, 
Ni-IDA and Ni-NTA. Much purer protein was obtained 
on the Ni-NTA resin than Ni-IDA resin (Fig. 3). Despite 
extensive washing, the final preparation of protein from 
the Ni-IDA resin contained impurities visible by Coo-
massie blue staining (Fig. 3A). In contrast, no impurities 
could be detected using Coomassie blue staining on the 
Ni-NTA resin (Fig. 3B). A test purification from 5 L of 
culture demonstrated that production could be scaled up 
for larger quantities (Fig. 4).  
Recognition of rN-RAP2 by antibodies raised in 
mice - Mice immunized with rN-RAP2 in the presence 
of alum adjuvant developed high titers of anti-RAP2 an-
tibodies, demonstrating the immunogenicity of this pro-
tein fragment (data not shown).
To characterize the conformational and sequence 
epitopes in rN-RAP2, anti-rN-RAP2 antibodies from im-
munized mice were analyzed for their ability to recognize 
native RAP2 prepared from the Triton X-100 protein ex-
tract from both erythrocyte membranes and the insoluble 
fraction containing parasites. The extracts were blotted 
onto nitrocellulose membranes and incubated with anti-
rN-RAP2 sera from several mice (Fig. 5). Sera pooled 
from mice stimulated with alum adjuvant alone served 
as a negative control. In the soluble fraction, the pooled 
anti-rN-RAP2 sera recognized one protein of ~29 kDa. 
Two products of 70 kDa and 82 kDa were recognized in 
the insoluble fraction.
These results are similar to those of Stowers et al. 
(1996), who found that an anti-RAP1 mAb recognized 
the 65 kDa and 70 kDa products of RAP1 cleavage.  To-
gether with other fragments of 29 and 42 kDa, these prod-
ucts correspond to uncleaved and cleaved forms of RAP2 
in Triton X-100 extracts from parasites. These products 
are formed prior to merozoite invasion (Howard et al. 
1998).  We chose to focus on rN-RAP2 rather than full-
length RAP2 in our work because the former can be pro-
duced in much higher yields and is sufficient to induce 
Fig. 1: confirmation of the identity of the 585 bp fragment containing 
the N-terminal residues 5-190 of Plasmodium falciparum rhoptry-
associated protein 2 (RAP2). The sequence of the cloned N-terminal 
of P. falciparum (N-RAP2) DNA was confirmed using the Thermo 
sequenase primer cycle sequencing kit.
Fig. 2: confirmation of the presence of the hexahistidine tag in the N-
terminal of Plasmodium falciparum (rN-RAP2) protein. Western blots 
showing binding of the protein by a commercially available monoclonal 
anti-histidine antibody.  Antibody binding was revealed using an anti-
mouse IgG antibody conjugated to peroxidase. The blot shows the fusion 
protein to have a mass of 27-29 kDa, consistent with the prediction.
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Additionally, rN-RAP2 was recognized by serum from 
a malaria patient who developed anemia during infec-
tion (Fig. 6), demonstrating that this patient had anti-
bodies against sequence epitopes found in our protein 
fragment. The successful purification of rN-RAP2 may 
permit epidemiologic studies aimed at determining the 
prevalence of anti-RAP2 antibodies in malaria patients 
with or without severe anemia and understanding the 
role of this target in the pathology of anemia in patients 
with falciparum malaria. 
Fig. 3: a comparison of N-terminal of Plasmodium falciparum (rN-RAP2) purification using two different nickel affinity columns. SDS-PAGE 
analysis of rN-RAP2 purification using two commercially available columns. A: two eluates from a iminodiacetic (Ni-IDA) column contained 
impurities visible following by Coomassie blue staining; B: two eluates from a nitrilotriacetic (Ni-NTA) column showed no detectable impuri-
ties following Coomassie blue staining; C: improvement of rN-RAP2 purification. Higher yields of protein were achieved by increasing the cul-
ture volume and using the inexpensive inducer d-lactose. The protein elutes from a Ni-NTA column in two fractions, as shown by SDS-PAGE.
the production of specific polyclonal antibodies in mice 
that recognize RAP2 from two strains of P. falciparum. 
Furthermore, the fact that anti-rN-RAP2 antibodies 
recognize a cleaved form of RAP2 as well as two prod-
ucts of RAP1 processing indicates that (i) both antigens 
share sequence epitopes and (ii) these epitopes reside 
within the first 180 residues of RAP2.    
Epitopes associated with host-parasite interaction in 
falciparum malaria - Recent studies have shown that the 
RSP2, a protein derived of rhoptry encoded by a RAP2 
gene, is discharged onto the surface of both infected and 
UEs and erythroid precursor cells in the bone marrow of 
malaria patients (Douki et al. 2003, Layez et al. 2005). 
A mAb against RSP2 was able to detect rN-RAP2 (Fig. 
6, Lane 2). This result shows that the recombinant N-
terminal fragment of RAP2 protein expressed in E. coli 
possesses epitopes similar to those implicated in the mo-
lecular mechanism of host-parasite interaction in falci-
parum anemia (Douki et al. 2003, Layez et al. 2005). 
Fig. 4: characterization of cross-reactivity epitopes in N-terminal of 
Plasmodium falciparum (rN-RAP2). Western blot using anti-rNRAP2 
mice IgG against extracts from two P. falciparum strains. Lanes A: 
recognition of proteins of ~70 and 82 kDa from insoluble Triton X-100 
extracts. These bands correspond to two products of RAP1 cleavage; 
B: a 29-kDa band corresponding to a cleavage product of RAP2.
Fig. 5: detection of a functional epitope associated with host-parasite 
interaction in falciparum malaria. Western blot of two extracts of Es-
cherichia coli BL21 pLysS containing rhoptry-associated protein 2 
(RAP2-pRSET) construct under (1) non-inducing and (2) inducing 
conditions. An anti-ring surface protein 2 (RSP2) monoclonal anti-
body was used as the primary antibody and goat anti-mouse IgG per-
oxidase was used as the secondary antibody. The protein (~29 kDa) 
present in the induced extract was recognized by an antibody against 
RSP2, demonstrating the presence of a target epitope on the expressed 
N-terminal of Plasmodium falciparum (rN-RAP2).  This suggests that 
the N-terminal fragment contains an epitope involved in the host-par-
asite interactions in falciparum malaria recently described by Douki 
et al. (2003) and Layez et al. (2005).
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Fig. 6: recognition of N-terminal of Plasmodium falciparum (rN-
RAP2) by sera of patients who developed anemia during malaria. 
Western blotting shows recognition of rN-RAP2 by human sera. A: 
serum from a human exposed to malaria. Two black spots were made 
with pencil to allow precise placement of the protein on the nitrocel-
lulose. Goat anti-human peroxidase was used as the secondary anti-
body; B: serum from an individual with no past history of malaria 
served as the negative control. 
DISCUSSION
The rhoptry organelles in the invasive merozoite form 
of Plasmodium species are thought to play a central role 
in the invasion of erythrocytes (Howard & Reese 1990). 
More specifically, they have been implicated directly in 
the sequence of events leading to host cell invasion, PV 
membrane formation and maintenance of the blood stage 
of the parasite cycle. 
Here, we present a cost-effective method of RAP2 
production developed by modifying the solubilization 
and purification methods of Stowers et al. (1995).  In 
contrast to these researchers who used the full-length 
protein, we worked with the recombinant N-terminal 
fragment of RAP2 and achieved purification in denatur-
ing conditions using 8 M urea.  We eluted the recom-
binant protein using a pH gradient. Our results further 
indicate that the N-terminus portion has epitopes that 
are common to RAP1 and recognized by the immune 
system of patients exposed to malaria. 
Initially, we obtained only very low levels of rN-
RAP2. The fragment was undetectable by SDS-PAGE 
and Coomassie blue, but it could be observed in Western 
blots using a commercially-available mAb against hexa-
histidine. Saul et al. (1992) reported similar results when 
expressing this protein in E. coli clone SG13009 using 
the pDS56/RBSII hexahistidine vector. Many factors 
(e.g., the fact that RAP2 is a lipophylic protein) could 
contribute to this difficulty. The full-length protein con-
tains five cysteines and codons rarely used in E. coli. 
Our N-terminal fragment has three of these cysteins and 
three rare codons. According to expression protocols, 
the oxidation of these cysteines may also make expres-
sion and solubilization difficult for inhibit growth of the 
host cells and rare codons can lead to a high level of 
frame shifting (QIAexpressionist 2003).  
We have observed that d-lactose is as efficient as 
IPTG for inducing the expression of recombinant protein 
(data not shown). However, we did not compare expres-
sion yields in side-by-side experiments with d-lactose 
and IPTG as done by Woyski & Cupp-Vickery (2001), 
who performed such a comparison when inducing the 
expression of cytochrome P450s with d-lactose. Accord-
ing to these authors, IPTG is the most expensive compo-
nent of expression experiments and its use at a concen-
tration of 1 mM results in a cost of ~$6.00/L of culture. 
In large-scale fermentation, the cost of IPTG could be-
come significant; in our studies, for example, the IPTG 
for a 5 L production run would cost $30. Instead, we 
used d-lactose at 10 g/L. This compound has a total cost 
of $0.30 ($0.06/L), which is 100 fold less expensive than 
IPTG.  In this way, we removed the inducing agent as the 
most expensive part of expression. 
Purification of rN-RAP2 on Ni-IDA resin was less 
efficient than that on Ni-NTA resin. Despite extensive 
washing using a gradient of 5-90 mM iDB, the eluate 
from the Ni-IDA contained impurities visible by Coo-
massie blue staining (Fig. 3A). However, using the Ni-
NTA resin and performing the wash step with denatur-
ation buffer at pH 6.3 and a quick gradient of 5, 10, 15 
and 20 mM iDB was sufficient to eliminate Coomassie-
visible impurities in the eluate (Fig. 3B). This difference 
in purification power may be due to the fact that Ni-IDA 
has only three metal-chelating sites and is unable to bind 
metal ions tightly. This weak binding leads to ion leach-
ing when the resin is loaded with strongly chelating pro-
teins and peptides or during wash steps. This results in 
low yields, impure products and metal-ion contamina-
tion of isolated proteins. In contrast, the Ni-NTA resin 
is a tetradentate chelating agent that binds nickel ions 
at four of the six ligand binding sites, leaving two sites 
free to interact with the His affinity tag. This means that 
Ni-NTA can bind metal ions much more tightly than Ni-
IDA and it can retain them even under stringent wash 
conditions (QIAexpressionist 2003).
The data shown here indicate that rN-RAP2 pro-
duced by a convenient and inexpensive protein expres-
sion system in prokaryotes can elicit an IgG response in 
mice and that the antisera produced can recognize native 
antigens from two strains of P. falciparum. Our results 
show that rN-RAP2 shares at least one cross-reactive 
epitope with RAP1. The same data were found by Stow-
ers et al. (1996), who detected 65 and 70 kDa products 
of RAP1 processing during merozoite invasion as well 
as other bands of 29 and 42 kDa in Triton X-100 parasite 
extracts. All of these bands correspond to uncleaved and 
cleaved forms of RAP2 (Howard & Reese 1998). 
Stowers et al. (1996) demonstrated that anti-RAP2 
antibodies cross-react with several linear epitopes of 
RAP1, such as C3LTEFSKLY12 in RAP2 and L202TPLEE-
LY209 in RAP1. The authors noted that the cross-reactiv-
ity of anti-RAP2 antibodies with RAP1 occurs because 
the epitopes in the two proteins are identical in three of 
the four flanking amino acids (underlined). This region 
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of RAP1 has been shown to inhibit parasites in vitro and 
confer partial protection in monkeys (Ridley et al. 1990). 
RAP1 and RAP2, together with a poorly understood 
third protein RAP3, form a low molecular weight com-
plex within the rhoptries of P. falciparum. Experiments 
in which the RAP1 gene was disrupted have shown that 
RAP1 is required to localize RAP2 to rhoptries. RAP1 
normally exists in complexes with RAP2 and RAP3, and 
some of these complexes are stabilized through mero-
zoite invasion and the development of young ring–stage 
parasites (Balbi et al. 2002). Moreover, anti-RAP1 anti-
bodies immunoprecipitate both RAP1 and RAP2 (Stow-
ers et al. 1996). However, truncation mutants of RAP1 
cause mislocalization of RAP2 but do not affect the ef-
ficiency of in vitro blood-stage growth.  These results 
have suggested that the low molecular weight complex 
is not required for P. falciparum invasion and growth 
in human erythrocytes (Baldi et al. 2000), supporting 
the idea anti-RAP2 antibodies may not be involved in 
protection against the parasite.  
The fact that rN-RAP2 could be detected by the same 
mAb that recognized the RSP2 attached on the surface 
of infected and UEs and by serum from a malaria patient 
who developed anemia indicates that the recombinant 
protein can still be recognized by the immune system. 
We have thus achieved the recombinant expression of 
rN-RAP2 containing a “ligand” sequence involved in 
the host-parasite interaction for attaching onto surface 
of infected and UEs. 
Future studies with rN-RAP2 may permit better un-
derstanding of this target in the pathology of anemia in 
patients with falciparum malaria. Our expression system 
may therefore prove valuable for generating an immuno-
genic protein fragment for epidemiological studies de-
signed to evaluate the effects of the anti-RAP2 immune 
response in anemic malaria patients. 
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